Additionally, Lavallée et al.’s study confirmed that 45% of AML patients with KMT2A gene rearrangement were mutated for components of the RAS pathway, with a BRAF mutation rate of 3.2% (1/31) [17]. This evidence concerns the gene KMT2A and acute myeloid leukemia.